Literature DB >> 12672581

Prolonged survival in AIDS-related progressive multifocal leucoencephalopathy following anti-retroviral therapy and cidofovir.

M T M Roberts1, A Carmichael, A M L Lever.   

Abstract

We describe the case of a 44-year-old man who developed sub-acute cerebellar ataxia due to AIDS-related progressive multifocal leucoencephalopathy (PML) caused by JC virus. Following treatment with highly active anti-retroviral therapy (HAART) and cidofovir, he made a marked neurological improvement and is leading an independent life 18 months after the diagnosis of PML. Early recognition of AIDS-related PML and treatment with HAART improves prognosis. Cidofovir, an inhibitor of viral DNA polymerase, appears to have an additive beneficial effect and should be considered especially in patients who fail to improve despite treatment with HAART and in patients who have a high JC virus load in CSF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672581     DOI: 10.1016/s0924-8579(02)00393-x

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  3 in total

1.  Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report.

Authors:  Halvor Naess; Solveig Glad; Anette Storstein; Christine H Rinaldo; Sverre J Mørk; Kjell-Morten Myhr; Hans Hirsch
Journal:  BMC Neurol       Date:  2010-05-18       Impact factor: 2.474

2.  Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells.

Authors:  D Topalis; I Lebeau; M Krecmerová; G Andrei; R Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy.

Authors:  Christoffer Kraemer; Stefan Evers; Thorsten Nolting; Gabriele Arendt; Ingo W Husstedt
Journal:  J Neurol       Date:  2008-01-18       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.